Express Pharma

CDSCO approves AstraZeneca’s Dapagliflozin with additional indication for treating CKD and heart failure patients

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalisation for heart failure in adults with Chronic Kidney Disease (CKD)

1 202

The Central Drugs Standard Control Organization (CDSCO) has approved AstraZeneca’s anti-diabetic drug